AAAAAA

   
Results: 1-3 |
Results: 3
A phase II study of [Y-90] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy
Authors: Kahn, D Austin, JC Maguire, RT Miller, SJ Gerstbrein, J Williams, RD
Citation: D. Kahn et al., A phase II study of [Y-90] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy, CANC BIO R, 14(2), 1999, pp. 99-111
Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer
Authors: Manyak, MJ Hinkle, GH Olsen, JO Chiaccherini, RP Partin, AW Piantadosi, S Burgers, JK Texter, JH Neal, CE Libertino, JA Wright, GL Maguire, RT
Citation: Mj. Manyak et al., Immunoscintigraphy with indium-111-capromab pendetide: Evaluation before definitive therapy in patients with prostate cancer, UROLOGY, 54(6), 1999, pp. 1058-1063
Comparison of clinical staging algorithms and (111)indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients
Authors: Polascik, TJ Manyak, MJ Haseman, MK Gurganus, RT Rogers, B Maguire, RT Partin, AW
Citation: Tj. Polascik et al., Comparison of clinical staging algorithms and (111)indium-capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients, CANCER, 85(7), 1999, pp. 1586-1592
Risultati: 1-3 |